Published in J Clin Psychiatry on March 23, 2010
Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders (ACCESS) | NCT01081418
Assessing the efficacy of a modified assertive community-based treatment programme in a developing country. BMC Psychiatry (2010) 0.96
The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci (2014) 0.91
Evaluation of an integrated care program for schizophrenia: concept and study design. Eur Arch Psychiatry Clin Neurosci (2014) 0.86
What contributes to good patient outcomes in the home treatment of the severely mentally ill: study protocol of a multi-centre analysis. BMC Psychiatry (2013) 0.82
Effectiveness and efficiency of integrated mental health care programmes in Germany: study protocol of an observational controlled trial. BMC Psychiatry (2014) 0.78
Efficacy of community treatments for schizophrenia and other psychotic disorders: a literature review. Front Psychiatry (2013) 0.75
Comprehensive early intervention for patients with first-episode psychosis in Japan (J-CAP): study protocol for a randomised controlled trial. Trials (2011) 0.75
Structures and processes necessary for providing effective home treatment to severely mentally ill persons: a naturalistic study. BMC Psychiatry (2016) 0.75
Should we listen and talk more to our patients? World Psychiatry (2013) 0.75
Are Users Satisfied with Assertive Community Treatment in Spite of Personal Restrictions? Community Ment Health J (2016) 0.75
Does one size really fit all? The effectiveness of a non-diagnosis-specific integrated mental health care program in Germany in a prospective, parallel-group controlled multi-centre trial. BMC Psychiatry (2017) 0.75
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry (2009) 3.56
High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation (2005) 3.06
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry (2007) 2.25
Integrated structural analysis of the human nuclear pore complex scaffold. Cell (2013) 2.25
Parvovirus B19 infection mimicking acute myocardial infarction. Circulation (2003) 2.03
Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry (2003) 1.73
Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry (2006) 1.69
Evaluation of the Two-Way Communication Checklist as a clinical intervention. Results of a multinational, randomised controlled trial. Br J Psychiatry (2004) 1.61
Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial. Addiction (2011) 1.59
Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis. Heart (2010) 1.57
Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine. Int J Neuropsychopharmacol (2005) 1.50
[Early detection of psychosis in children and adolescents - have developmental particularities been sufficiently considered?]. Z Kinder Jugendpsychiatr Psychother (2011) 1.40
Monolithic materials: Promises, challenges, achievements. Anal Chem (2006) 1.36
Monolithic capillary-based ion-selective electrodes. Anal Chem (2005) 1.36
Memory and attention performance in psychiatric patients: lack of correspondence between clinician-rated and patient-rated functioning with neuropsychological test results. J Int Neuropsychol Soc (2004) 1.25
Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry (2007) 1.21
Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol (2009) 1.19
Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs (2004) 1.18
Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. Dialogues Clin Neurosci (2010) 1.17
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry (2005) 1.16
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol (2006) 1.15
Two-dimensional reversed-phase x ion-pair reversed-phase HPLC: an alternative approach to high-resolution peptide separation for shotgun proteome analysis. J Proteome Res (2007) 1.13
Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells. Blood (2010) 1.11
Genome-wide association study in German patients with attention deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2011) 1.09
Absolute myoglobin quantitation in serum by combining two-dimensional liquid chromatography-electrospray ionization mass spectrometry and novel data analysis algorithms. J Proteome Res (2006) 1.07
Application of integrated transcriptomic, proteomic and metabolomic profiling for the delineation of mechanisms of drug induced cell stress. J Proteomics (2012) 1.06
Statistical learning of peptide retention behavior in chromatographic separations: a new kernel-based approach for computational proteomics. BMC Bioinformatics (2007) 1.05
Basic symptoms and the prediction of first-episode psychosis. Curr Pharm Des (2012) 1.05
Impact of duration of untreated psychosis on pre-treatment, baseline, and outcome characteristics in an epidemiological first-episode psychosis cohort. J Psychiatr Res (2008) 1.05
Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res (2008) 1.04
From nature versus nurture, via nature and nurture, to gene x environment interaction in mental disorders. Eur Child Adolesc Psychiatry (2009) 1.02
Assessing protein immunogenicity with a dendritic cell line-derived endolysosomal degradome. PLoS One (2011) 1.02
Separation, detection, and identification of peptides by ion-pair reversed-phase high-performance liquid chromatography-electrospray ionization mass spectrometry at high and low pH. J Chromatogr A (2005) 1.02
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? Biol Psychiatry (2006) 1.01
Depression, anxiety, and disturbed sleep in glaucoma. J Neuropsychiatry Clin Neurosci (2013) 1.00
Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv (2012) 1.00
Subjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiol Psichiatr Soc (2008) 1.00
Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol (2005) 1.00
Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol (2010) 1.00
Improving treatment adherence in your patients with schizophrenia: the STAY initiative. Clin Drug Investig (2013) 0.99
Rationale and content of psychenet: the Hamburg Network for Mental Health. Eur Arch Psychiatry Clin Neurosci (2012) 0.99
The near Babylonian speech confusion in early detection of psychosis. Schizophr Bull (2011) 0.98
SIMPATIQCO: a server-based software suite which facilitates monitoring the time course of LC-MS performance metrics on Orbitrap instruments. J Proteome Res (2012) 0.97
Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine. J Pharm Pharmacol (2004) 0.96
De novo peptide sequencing by tandem MS using complementary CID and electron transfer dissociation. Electrophoresis (2009) 0.95
The facial pattern of disgust, appetence, excited joy and relaxed joy: an improved facial EMG study. Scand J Psychol (2005) 0.95
'A rose is a rose is a rose', but at-risk criteria differ. Psychopathology (2012) 0.94
A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia. Health Expect (2011) 0.94
Integrated care in patients with schizophrenia: results of trials published between 2011 and 2013 focusing on effectiveness and efficiency. Curr Opin Psychiatry (2013) 0.93
The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential. J Pineal Res (2010) 0.93
Prevalence of HBV genotypes in Central and Eastern Europe. J Med Virol (2008) 0.92
Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin (2010) 0.92
Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders. Schizophr Res (2009) 0.92
Infectious pulmonary complications after stem cell transplantation or chemotherapy: diagnostic yield of bronchoalveolar lavage. Diagn Microbiol Infect Dis (2005) 0.92
What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. Eur Arch Psychiatry Clin Neurosci (2014) 0.92
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol (2012) 0.92
Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients. Schizophr Res (2002) 0.91
Depression in Alzheimer's disease might be associated with apolipoprotein E epsilon 4 allele frequency in women but not in men. Dement Geriatr Cogn Disord (2002) 0.91
Childhood trauma and dissociation in female patients with schizophrenia spectrum disorders: an exploratory study. J Nerv Ment Dis (2006) 0.91
Proteome analysis of Myxococcus xanthus by off-line two-dimensional chromatographic separation using monolithic poly-(styrene-divinylbenzene) columns combined with ion-trap tandem mass spectrometry. J Proteome Res (2006) 0.91
Improving peptide identification in proteome analysis by a two-dimensional retention time filtering approach. J Proteome Res (2009) 0.91
Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial). J Clin Psychiatry (2012) 0.90
Comparative sequencing of nucleic acids by liquid chromatography-tandem mass spectrometry. Anal Chem (2002) 0.90
Characterization of some physical and chromatographic properties of monolithic poly(styrene-co-divinylbenzene) columns. J Chromatogr A (2004) 0.90
High-efficiency nano- and micro-HPLC--high-resolution Orbitrap-MS platform for top-down proteomics. Proteomics (2010) 0.90
The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry (2006) 0.90
Monolithic capillary columns for liquid chromatography-electrospray ionization mass spectrometry in proteomic and genomic research. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 0.89
Decision-making in localized prostate cancer: lessons learned from an online support group. BJU Int (2010) 0.89
Separate analysis of DYS385a and b versus conventional DYS385 typing: is there forensic relevance? Int J Legal Med (2004) 0.88
Common obesity risk alleles in childhood attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet (2013) 0.88
What percentage of people in the general population satisfies the current clinical at-risk criteria of psychosis? Schizophr Res (2010) 0.88
Workflows for automated downstream data analysis and visualization in large-scale computational mass spectrometry. Proteomics (2015) 0.87
Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res (2009) 0.87
Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord (2003) 0.87
Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics. Expert Opin Pharmacother (2014) 0.87
Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: results from a survey conducted across Europe, the Middle East, and Africa. Patient Prefer Adherence (2013) 0.87
Hydrophobic, pellicular, monolithic capillary columns based on cross-linked polynorbornene for biopolymer separations. Anal Chem (2002) 0.87
Automated de novo sequencing of nucleic acids by liquid chromatography-tandem mass spectrometry. J Am Soc Mass Spectrom (2004) 0.87
Pretreatment and outcome correlates of past sexual and physical trauma in 118 bipolar I disorder patients with a first episode of psychotic mania. Bipolar Disord (2010) 0.87
Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and their relation to recovery criteria in 2842 patients followed over 3 years. Schizophr Res (2008) 0.86
Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy. J Med Virol (2003) 0.86
Child and adolescent psychiatric genetics. Eur Child Adolesc Psychiatry (2010) 0.86
Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl) (2007) 0.86
Dopaminergic modulation of probabilistic reasoning and overconfidence in errors: a double-blind study. Schizophr Bull (2013) 0.86
Capillary scale monolithic trap column for desalting and preconcentration of peptides and proteins in one- and two-dimensional separations. J Chromatogr A (2006) 0.86
Identification of bacteria by polymerase chain reaction followed by liquid chromatography-mass spectrometry. Anal Chem (2005) 0.86